Exciting non-invasive blood glucose monitor details promised by Afon for upcoming ATTD Conference
Just recently, Afon took to Twitter to share news about its non-invasive blood glucose monitor. Along with stating in no uncertain terms that the wearable would be “coming soon”, the healthtech startup also revealed that tests had been very positive in terms of accuracy. Now it seems that it won’t be too much longer before those who are hopeful about the wearable monitor might learn even more specific details about the life-changing Afon device.
Apparently, Afon will be attending the Advanced Technologies & Treatments for Diabetes (ATTD) Conference, which is being held in Barcelona, Spain from 27 to 30 April. In addition, the company has made this bold statement: “we will be presenting exciting new data from our wearable, no-invasive [sic] blood glucose monitor”. The monitor is a needle-free solution that can either be worn as a sole wearable or as part of a smartwatch.
This momentum for Afon has been a long time coming; we reported about the wearable back in November of last year and work has been in progress on the specialist diabetes management device for long before that. Even in December 2019, Afon was hoping to have “a product on the market within 2 years”. Obviously, the COVID-19 pandemic slowed R&D at a global level for everyone, so it is understandable that there has been some delay.
Unfortunately, no projected cost for the Afon device has been made publicly available yet, but it could be comparatively economical due to the lack of requirement for part replacement. The ATTD attendance and new data promise demonstrates Afon’s supreme confidence in its blood glucose monitor, and it’s likely larger firms like Dexcom and Abbott will be keeping a watchful eye on what is about to be revealed by this Monmouthshire, Wales-based outfit.